Pilot study of (89)Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer.
Pilot study of (89)Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer.
复制标题
DOI：
10.1186/s13550-014-0035-5
复制
发表时间：
2014-12
期刊：
影响因子：
3.2
通讯作者：
Smit EF
中科院分区：
文献类型：
--
作者：
Bahce I;Huisman MC;Verwer EE;Ooijevaar R;Boutkourt F;Vugts DJ;van Dongen GA;Boellaard R;Smit EF
这项初步研究的目的是评估非小细胞肺癌（NSCLC）肿瘤中89 Zr-贝伐珠单抗的摄取是否可以可视化和定量。探索了肿瘤89 Zr-贝伐珠单抗摄取与肿瘤对基于贝伐珠单抗的方案的抗肿瘤治疗的应答之间的相关性。7名NSCLC患者在注射36.4 ± 0.9 MBq（平均值± SD）89 Zr-贝伐珠单抗后第4天和第7天接受静态PET扫描，然后开始卡铂-紫杉醇-贝伐珠单抗化疗（CPB）。CPB后接受贝伐珠单抗维持治疗的总生存期（OS）和无进展生存期（PFS）与肿瘤示踪剂摄取相关，使用标准化摄取峰值（SUV峰值）进行定量。在第4天和第7天，肿瘤组织（原发性肿瘤和转移瘤）中的Zr-贝伐珠单抗摄取（SUV峰值）比非肿瘤组织（健康肌肉、肺和脂肪）高约4倍。SUV峰值与OS或PFS之间存在正相关趋势，但无显著相关性。这项初步研究表明，89 Zr-贝伐单抗PET成像在NSCLC中是可行的。需要进一步研究以验证该技术作为选择患者进行贝伐单抗治疗的预测性生物标志物。本文的在线版本（doi：10.1186/s13550 - 014 - 0035 - 5）包含补充材料，可供授权用户使用。
The aim of this pilot study was to evaluate whether the uptake of 89Zr-bevacizumab in non-small cell lung cancer (NSCLC) tumors could be visualized and quantified. The correlation between tumor 89Zr-bevacizumab uptake and tumor response to antitumor therapy with a bevacizumab-based regimen was explored. Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4 ± 0.9 MBq (mean ± SD) 89Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB). Overall survival (OS) and progression-free survival (PFS) to CPB followed by bevacizumab maintenance therapy was correlated to tumor tracer uptake, quantified using peak standardized uptake values (SUVpeak). Zr-bevacizumab uptake (SUVpeak) was approximately four times higher in tumor tissues (primary tumor and metastases) than in non-tumor tissues (healthy muscle, lung, and fat) on days 4 and 7. A positive trend but no significant correlation could be found between SUVpeak and OS or PFS. This pilot study shows that 89Zr-bevacizumab PET imaging in NSCLC is feasible. Further investigation to validate this technique as a predictive biomarker for selecting patients for bevacizumab treatment is warranted. The online version of this article (doi:10.1186/s13550-014-0035-5) contains supplementary material, which is available to authorized users.